Abstract: Approximately 50% of melanoma patients carry a mutation in the BRAF protein. Targeted therapy with inhibitors of BRAF and the downstream pathway is very effective in these patients, but long-term benefits are limited due to the onset of therapy resistance. Previous studies demonstrated that BRAF inhibitors (BRAFi) positively affect the antitumor immune response mediated by T cells. Disclosed are methods of treating, preventing, inhibiting, reducing, and/or ameliorating a cancer and/or metastasis in a subject using an adoptive T cell therapy, the method comprising administering to the subject a BRAF inhibitor (BRAFi) (such as, for example, sorafenib, vemurafenib, dabrafenib, and/or encorafenib) and an adoptive T cell therapy, wherein administration of the BRAF inhibitor increases insulin-like growth factor II receptor (IGF2R).